🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

· daily

Biotech Small-Cap Approvals — October 09, 2026

This digest covers a single FDA approval recorded for the period October 09, 2026 to October 09, 2026, within the Biotech Small-Cap Approvals stream. The approval mix is 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other action, so no first-in-class or new molecular entity signal is present. The only event is the SHANDONG approval of sugammadex sodium, classified in the source data as a FALLBACK approval type and labeled a biosimilar in its summary, though the analysis rests on limited detail. With one approval and a neutral signal (strength 5/10, materiality 5/10), no therapeutic area cluster or sector theme can be established from this period. The key watch item is whether the classification and commercial terms for sugammadex are confirmed, since peak sales, exclusivity, pricing power, and market position are all NOT_DISCLOSED.

1 total filings
· daily

Orphan Drug Approvals — October 09, 2026

This digest covers a single FDA action in the Orphan Drug Approvals stream for the period October 9, 2026, with the approval mix at 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other action. The sole approval is a label expansion-category action recorded as FALLBACK for TUCATINIB (TUKYSA) from SEAGEN, dated October 7, 2026, carrying a bullish signal (strength 5/10, materiality 5/10). No therapeutic area clustering is observable from a single data point, so no sector-level momentum signal can be drawn. The highest-conviction signal is the bullish read on SEAGEN's continued commercial support of TUKYSA, but the source data does not disclose the indication, peak sales, exclusivity, pricing power, or market position, limiting the investment conclusion. The key watch item is that the approval type is classified as FALLBACK rather than a standard label expansion, which warrants verification of the regulatory pathway and scope before sizing any position.

1 total filings
· daily

New Drug Approvals (Original) — October 09, 2026

This digest covers a single FDA approval recorded between October 9, 2026 and October 9, 2026, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other approval. The lone event is SUGAMMADEX SODIUM from SHANDONG, categorized under a FALLBACK approval pathway and flagged as a biosimilar-type approval in the source analysis, with a neutral signal (strength 5/10, materiality 5/10). No therapeutic area clustering is observable from one approval, so no sector momentum signal can be drawn. Commercial parameters including peak sales, exclusivity, pricing power, and market position are NOT_DISCLOSED, limiting the depth of investment conclusions. The primary watch item is the lack of disclosed market-position and exclusivity data, which means the commercial read-through for originator Merck or competing sugammadex generics cannot be quantified from the provided data.

1 total filings
· daily

DHS Homeland Security Contracts — October 09, 2026

The eight DHS awards in this period total $178,083,908 in obligations, all civilian and none defense-related, with CBP and USCIS as the dominant buyers and IT, cybersecurity, facilities, and biometric R&D as the core scopes. The highest-conviction signal is the USCIS time-and-materials delivery order to SALIENT CRGT (parent GOVCIO, LLC), with a $23,895,601 current obligation inside a $163,395,565 ceiling and a potential end date of 2030-11-06, though only about 15% of the ceiling is currently obligated. Awards are split between open-competition wins (SAIC, Anduril, Accenture Federal, Definitive Logic, SALIENT CRGT) and set-aside or small-business awards (Spatial Front's 8(a) order, Brown Point's woman-owned small business order). Most recipients are private or have no public-market linkage evident in the data, so equity impact is largely indirect; the watch item is option exercise and outlay pace across the largest orders, particularly SALIENT CRGT's 2026-11-06 current end date. Signals are uniformly neutral in the source analyses, and this digest does not inflate the bullish count.

8 total filings
· daily

VA Healthcare & Services Contracts — October 09, 2026

The 16 VA Healthcare & Services contracts total $1,139,115,013 in obligations, with zero defense-related awards; the entire stream is civilian, dominated by Department of Veterans Affairs construction, facilities, and IT/services work. The highest-materiality award is TriWest Healthcare Alliance Corp's $900,485,186 delivery order, which accounts for about 79% of the aggregate but shows $0 outlayed and a one-month performance period, so its recurrence is unverified. Beyond that outlier, the remaining 15 awards range from roughly $10.9M to $23.9M, are overwhelmingly set-aside construction contracts to SDVOSBs, and show $0 outlayed in most cases, meaning realized revenue is largely unestablished. The highest-conviction signal is the scale and concentration of the TriWest award as a single-agency demand event, while the principal watch item is whether outlays materialize against these obligations, since the stream's average signal strength is only 3.1/10 and no contract in the set can be tied to a publicly traded parent from the data provided.

16 total filings
· daily

HHS & Healthcare Contracts Intelligence — October 09, 2026

Two HHS/ASPR (BARDA) healthcare R&D contracts totaling $110,661,632 in obligations were recorded for the period, with zero defense-related awards, so the entire digest sits in the civilian HHS/healthcare stream. The dominant theme is BARDA funding for medical countermeasure and diagnostic readiness: Abbott Laboratories received $65,469,510 for clinical validation supporting an expanded FDA indication for its TBI diagnostic, and Basilea Pharmaceutica International received $45,192,122 in a cost-sharing contract for antibiotics against drug-resistant gram-negative bacteria. The highest-conviction signal is the Abbott award, given its scale, firm-fixed-price structure, and clear path to an FDA marketing application, though this is government R&D funding rather than product revenue and only about 21% of its obligation has been outlayed. Both signals are rated neutral (average strength 3.5/10), and the key watch item is the outlay pace and option exercise on Basilea's contract, where only about 45% of the current obligation has been spent against a $191,938,367 ceiling. Revenue materiality to either parent company cannot be established from the provided data.

2 total filings
· daily

New Federal Contractors — October 09, 2026

The 30 new federal contracts in this period carry a combined obligation of $1,703,692,365, with zero defense-related awards, so the entire digest falls on the civilian side of the procurement ledger. The largest award is TriWest Healthcare Alliance Corp's $900,485,186 Department of Veterans Affairs order, but it covers a one-month performance period and shows $0 outlayed, so its headline value is not a reliable proxy for realized revenue. Civilian agency themes are dominated by the Department of Veterans Affairs (facility construction and health administration), Forest Service wildfire aviation (Neptune Aviation Services, AERO AIR, Billings Flying Service, Helicopter Transport Services, ROTAK), and DHS/CBP and USCIS IT and cyber work (Accenture Federal Services, Anduril, SALIENT CRGT). The highest-conviction signal is the breadth of VA construction awards to service-disabled veteran-owned set-asides, while the principal watch item is execution risk: most of the largest awards show $0 or low outlays, leaving revenue recognition unproven. Signals are classified neutral across the board because most individual records lack public-parent or trend data needed to assign directional conviction.

30 total filings
· daily

Significant Contract Modifications ($10M+) — October 09, 2026

This digest covers 50 significant federal contract modifications ($10M+) with a combined obligation of $1,935,265,219, none of which are defense-related; the entire stream is civilian-agency spending led by VA, HHS, DHS, USDA and GSA. The dominant themes are VA facilities construction (many small SDVOSB set-asides), CDC/CMS IT and health services, DHS/CBP and USCIS IT and aviation-adjacent work, and USDA Forest Service wildfire airtanker services. The single largest record, TriWest Healthcare Alliance's $900,485,186 VA delivery order, carries a one-month performance period and $0 outlayed, so its headline value is not a reliable revenue indicator. The average signal strength is 3.1/10 and no contract was classified as bullish or bearish, so conviction is low across the stream; the highest-conviction read is the consistent pattern of small-business and SDVOSB set-aside construction awards to private firms with no public-market linkage. The key watch item is outlay conversion: most recent awards show $0 outlayed, and many records lack public-parent identification, which limits translation into listed-equity impact.

50 total filings
· daily

Contract Deobligations Alert — October 09, 2026

The digest covers 30 federal contract records totaling $1,703,692,365 in aggregate obligation, all classified as civilian with zero defense-related awards. The mix is dominated by Department of Veterans Affairs construction and health-insurance orders, Department of Agriculture Forest Service airtanker and fire-aviation delivery orders, and Homeland Security IT and border-security work. The highest-materiality record is TriWest Healthcare Alliance's $900,485,186 VA delivery order, though its one-month performance window and $0 outlayed make the headline value an unreliable indicator of realized revenue. Nearly every record carries a neutral signal (average strength 3.2/10), so conviction is low across the set. The principal watch item is the gap between obligated and outlayed values, which ranges from $0 to roughly 84% spent, and the ambiguity around award-date versus performance-period sequencing in several records.

30 total filings
· daily

Contract Option Exercises — October 09, 2026

This digest covers 50 contract option exercise records dated October 9, 2026, aggregating $1,935,265,219 in total obligation with zero defense-related awards, so the entire stream is civilian (VA, HHS, DHS, USDA, GSA, NASA, Treasury, Education, PBGC). The dominant themes are VA facilities construction and staffing (many SDVOSB set-asides such as Valiant Construction, Briston Construction, and RBVETCO), USDA Forest Service wildfire aviation (Neptune Aviation, AERO AIR, Helicopter Transport Services, ROTAK, Billings Flying Service), and DHS/CBP and USCIS IT and cybersecurity services (Accenture Federal, SALIENT CRGT, Spatial Front, Definitive Logic). The highest-materiality award is TriWest Healthcare Alliance's $900,485,186 VA delivery order, but its single-month performance period and $0 outlays make it a poor proxy for recurring revenue. Average signal strength is only 3.1/10 and every contract is classified neutral, so conviction is low across the stream; the principal watch item is the large gap between obligated and ceiling values (e.g., Accenture Federal's $14.8M obligation against a $121.4M ceiling), which depends on option exercise that is not yet committed.

50 total filings
· daily

Federal Professional Services Contracts — October 09, 2026

Three federal professional services contracts totaling $104,013,229 in obligations were reviewed for the period October 9, 2026, with none defense-related (0 of 3) and all carrying neutral signals (average strength 2.7/10). The civilian mix is split across NASA (two awards totaling $86,854,494 in obligations, from AMERESCO SELECT, INC. at $48,129,004 and SOUTHWEST RESEARCH INSTITUTE at $38,725,490) and GSA (Deloitte Consulting LLP at $17,158,734). The dominant theme is long-duration civilian facilities-energy and space R&D spending, with NASA contracts running to 2029 and 2036 respectively. The highest-materiality award is AMERESCO SELECT's firm-fixed-price Wallops Island energy retrofit, though its public-equity relevance is not established in the data. The key watch item is that Deloitte's award has $0 outlayed and only about 9.7% of its $176,034,150 ceiling obligated, so near-term revenue recognition remains unproven.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — October 09, 2026

The 11 federal IT and cybersecurity awards dated 2022 through 2026 aggregate $231,292,955 in total obligation, with 0 of 11 defense-related and all 11 civilian (DHS, HHS, GSA, Treasury, VA). The dominant theme is DHS, which accounts for five awards (Anduril $42,066,939; SALIENT CRGT $23,895,601; DEFINITIVE LOGIC $16,499,505; Accenture Federal $14,823,471; SPATIAL FRONT $10,831,013), followed by HHS/CMS with three. The highest-conviction signal is Accenture Federal Services' CBP Cyber Security Operations Center delivery order ($14,823,471 obligated against a $121,415,324 ceiling), a large-prime cybersecurity win under full and open competition, though it has $0 outlayed so far. The most material risk is execution and conversion: Booz Allen Hamilton's GSA order ($38,452,810 obligated, $0 outlayed against a $373,036,880 ceiling) and Spatial Front's USCIS order (only $1,347,491 of $10,831,013 outlayed) show large headline values with little realized revenue. Several records lack public-company linkage, tickers, or financials, so direct equity impact is not established for most entities.

11 total filings
· daily

NASA & Space Contracts Intelligence — October 09, 2026

This digest covers a single NASA & Space Contracts Intelligence record from October 09, 2026, representing $12,413,999 in total obligation, all civilian and none defense-related (0/1 defense). The sole award is a non-competed cost-plus-fixed-fee delivery order from NASA Management Office - JPL to California Institute of Technology, a nonprofit university rather than a publicly traded company. Only about 17% ($2,114,426) of the current obligation has been outlayed against a $22,615,533 base-plus-options value running through 2028-09-30. The highest-conviction read is neutral: the award confirms an ongoing government-funded space R&D relationship but offers no direct equity exposure or budget-trend evidence. The key watch item is whether option exercises or modifications lift obligated value toward the full $22,615,533 ceiling, roughly $10.2 million of which currently depends on future government action.

1 total filings
· daily

All HHS Contracts — October 09, 2026

The 8 HHS contracts in this period carry a combined obligation of $198,613,842 with zero defense-related awards, so the entire set is civilian, spread across BARDA/ASPR (Abbott Laboratories, Basilea Pharmaceutica), CDC (CAS FSE JV II, NTT DATA, ATL International), and CMS (RELI Group, VERSA Integrated Solutions, eMagine IT). The dominant theme is health IT and facilities/application services sustainment rather than new platform spend, with CMS accounting for the bulk of the IT-services awards. The highest-materiality signal is Abbott Laboratories' $65,469,510 firm-fixed-price BARDA award for clinical validation of its TBI diagnostic, though it is R&D funding with only about $17.6M outlayed and no confirmed FDA decision. The average signal strength is 3.4/10 and every contract is classified neutral, so no contract supports a directional thesis on its own. The key watch item is Basilea Pharmaceutica's $45.2M obligation against a $191.9M ceiling, where option exercise would be the main driver of value, and the recipient's public-market exposure cannot be determined from the data.

8 total filings
· daily

Mega Contracts Monitor ($100M+) — October 09, 2026

This digest covers a single Mega Contracts Monitor ($100M+) record dated October 7-9, 2026, carrying a total obligation of $900,485,186, all civilian and none defense-related (0/1 defense count). The sole award is a Department of Veterans Affairs delivery order to TriWest Healthcare Alliance Corp, a Phoenix, AZ-based U.S.-owned firm, under a firm fixed-price structure awarded via full and open competition with no set-aside. The dominant theme is VA health insurance program administration (NAICS 524114, PSC G007), but the signal is weak: the performance period is only one month (2026-09-01 to 2026-09-30), outlays to date are $0, and the description suggests a periodic 'EXPRESS REPORT: FY26 SEPTEMBER' order rather than a multi-year program. The highest-conviction takeaway is that the headline value should not be read as realized revenue; the key watch item is whether the award date (2026-10-07) falling after the performance period signals a data or timing anomaly and whether similar orders recur.

1 total filings
· daily

High-Value Federal Grants ($5M+) — October 09, 2026

The 30 high-value federal grant and contract awards in this stream total $1,703,692,365 in obligations, with zero defense-related awards; all 30 are civilian (VA, HHS/BARDA, DHS, USDA Forest Service, NASA, GSA, Treasury, CDC and others). The dominant theme is Department of Veterans Affairs facilities and healthcare spending, led by TriWest Healthcare Alliance's $900,485,186 single-month delivery order, which is the largest single obligation but carries $0 outlays and a period-of-performance/award-date mismatch that makes its recurring value unverifiable. The highest-conviction signal is the steady USDA Forest Service aviation program, where multiple small-business and large-recipient airtanker and helicopter delivery orders (Neptune Aviation, Aero Air, Helicopter Transport Services, ROTAK, Billings Flying Service) show consistent multi-year wildfire demand, though most recipients are private. The key watch item is execution: most awards show low outlay ratios or $0 outlays, so obligated value should not be treated as realized revenue until invoicing data appears.

30 total filings
· daily

General Federal Contracts — October 09, 2026

The 51 contracts in this October 9, 2026 digest aggregate $1,944,020,447 in total obligation, but the figure is dominated by a single $900,485,186 TriWest Healthcare Alliance VA delivery order that carries $0 outlayed and no visible recurrence, so headline value overstates durable revenue. None of the 51 awards are defense-related; the stream is entirely civilian, concentrated in VA facilities and construction (roughly a dozen awards), USDA Forest Service wildfire aviation (Neptune Aviation, Billings Flying Service, Helicopter Transport Services, ROTAK, HELI-1, AERO AIR), and DHS/CBP/USCIS IT and facilities work (Accenture Federal, Salient CRGT, Anduril, Spatial Front). The highest-materiality contract with actual execution evidence is the Accenture Federal CBP cybersecurity delivery order ($14,823,471 obligated against a $121,415,324 ceiling), while the largest outlay-backed awards are Neptune Aviation's airtanker orders (about 82-83% outlayed). Average signal strength is 3.1/10 and every contract is classified neutral, so the digest offers no directional call; the key watch item is whether the TriWest order and the 2026-era VA construction awards convert to outlays on schedule.

51 total filings
· daily

All NASA Contracts — October 09, 2026

Three NASA contracts totaling $99,268,494 in obligations were awarded or active in the period, with zero defense-related awards, making this a purely civilian space and facilities-energy snapshot. The largest is AMERESCO SELECT, INC.'s $48,129,004 firm-fixed-price energy-conservation delivery order at NASA Goddard (Wallops Island, VA), followed by SOUTHWEST RESEARCH INSTITUTE's $38,725,490 cost-plus-fixed-fee JUICE ultraviolet spectrograph work at NASA Marshall and California Institute of Technology's $12,413,999 cost-plus-fixed-fee delivery order from NASA JPL. The dominant theme is sustained NASA science and facilities spending, but the data does not establish agency budget trends. The highest-conviction read is the AMERESCO award's long-dated firm-fixed-price structure, though its parent's public-equity status is unverified. The key watch item is outlay progression: only about 42%, 16% and 17% of the respective obligations have been disbursed, so most value remains contingent on future funding and option actions.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 09, 2026

Across the 10 newly reviewed S&P 500 technology filings for 2026-10-09, the dominant theme is heavy insider selling by senior executives, concentrated among software, networking, and semiconductor names: Arista's CEO disposed of roughly $15M plus two smaller tranches, Analog Devices' Chief Operations/Tech Officer sold about $2.2M across two transactions, Datadog's CTO sold about $5.05M after option exercises, and Accenture's COO sold about $264K. Most of these sales were executed under Rule 10b5-1 plans, which dampens the signal value of any single transaction, though the clustering across companies in a single session is worth monitoring. The one substantive financial filing is Micron's 10-K for the fiscal year ended September 3, 2026, which reports revenue of $133,188M versus $37,378M in FY2025 (up 256%), net income of $84,969M versus $8,539M, gross margin expanding to 81% from 40%, and operating cash flow of $89,675M versus $17,525M. Micron's effective tax rate rose to 14.8% from 11.6% and interest expense fell to $106M from $477M after several debt tranches were repaid, while management supported an increase in authorized share repurchases. Gifting activity at Palo Alto Networks and NVIDIA and a board appointment at Cisco are governance items with limited direct market impact. The Micron filing is the materiality outlier, and the insider-selling cluster is the main sentiment counterweight.

10 high priority 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — October 09, 2026

The 2026-10-09 NASDAQ-100 SEC filing stream is dominated by one standout fundamental report: Micron Technology's FY2026 10-K, which shows revenue of $133,188M (up 256% from $37,378M), net income of $84,969M versus $8,539M, gross margin expanding to 81% from 40%, and operating cash flow of $89,675M, supporting a larger buyback authorization. Balance sheet deleveraging is evident, with senior note repayments through 2026 and interest expense down to $106M from $477M, though the effective tax rate rose to 14.8% from 11.6%. The remaining filings are governance and insider-activity items: Cisco added independent director Girish Rishi (committee assignments pending), NVIDIA's director made a 500,000-share gift under a 10b5-1 plan, and Analog Devices' COO/CTO Vivek Jain sold roughly $2.2M of stock across two transactions. Strategy Inc's DEFA14A is an incomplete excerpt with no substantive content and is excluded from quantitative analysis. Portfolio-level, the signal set is semiconductor-heavy and points to strong AI-cycle earnings power alongside modest, largely routine insider selling.

4 high priority 1 medium 5 total filings